CompletedNCT01795547

Aripiprazole Compared With Paliperidone for Schizophrenia Maintenance

About this title

Medication studyAges 18–60United States

The study in practice

Understand this study

This study was for people with schizophrenia. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.

Listed locations: Los Angeles and 1 more locationSee all locations and recruitment
Study phase: Phase 3

Study clarity

Study start dateFebruary 2013

Recruitment status: Completed
Enrollment listed in the registry: 295
Sponsor: H. Lundbeck A/S
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: United States
Age range: From 18 Years to 60 Years
Official registry ID: NCT01795547
Official title: Show the full official title
A 28-week, Randomised, Open-label Study Evaluating the Effectiveness of Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia

Completed

Los Angeles · San Diego

FAQ

Who is behind this study?

The study sponsor is H. Lundbeck A/S.

Did this study involve medication?

Yes. The study involved medication, including Aripiprazole and aripiprazole once-monthly and Paliperidone and paliperidone palmitate.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.